Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data
Adagrasib/Keytruda Show Preliminary ORR Of 71%
The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.
